

10/10/01
JCC921 U.S. PTO

Please type a plus sign (+) inside this box



10-11-01

SUBSTITUTE for PTO/SB/05 (08/00) Utility Patent Application Transmittal
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Box Seez

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	20757Y
First Inventor or Application Identifier	
Title	Aza- and Polyaza-Naphthalenyl Carboxamides Useful As HIV Integrasaxe Inhibitors
Express Mail Label No.	EL523938307US



APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 444]</p> <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 1] [Total Pages 444]</p> <p>4. Oath or Declaration</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 14 completed)</p> <p>i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).</p> <p>5. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p>		
<p>6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <p>a. <input checked="" type="checkbox"/> Computer Readable Form</p> <p>b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)</p> <p>c. <input checked="" type="checkbox"/> Statements verifying identity of above copies</p>		
ACCOMPANYING APPLICATION PARTS		
<p>7. <input type="checkbox"/> Assignment papers (cover sheet & document(s))</p> <p>8. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</p> <p>9. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>10. <input type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>12. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>13. <input checked="" type="checkbox"/> Other: <u>Unsigned Oath & Declaration</u></p>		

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP) of prior application No. _____ / _____

Prior application information: Examiner: _____ Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	Customer No. 000210 (Insert Customer No. or Attach bar code here)				
NAME	Kenneth R. Walton				
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30				
CITY	Rahway	STATE	NJ	ZIP CODE	07065-0907
COUNTRY	USA	TELEPHONE	732-594- 3462	FAX	732-594-4720

Name	Kenneth R. Walton	Registration No. (Attorney/Agent)	32,951
Signature	<i>Kenneth R. Walton</i>		Date 10/10/2001

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 10, 2001

EXPRESS MAIL NO. EL523938307US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, BOX PATENT APPLICATION, WASHINGTON, D.C. 20231.

MAILED BY *A.B. Crowley* DATE *10/10/01*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

Deposit Acct. 13-2755
MERCK & CO., INC.
Our Case Docket No. 20757Y

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is the patent application of Inventor(s):
Neville J. Anthony, Robert P. Gomez, Steven D. Young, Melissa Egbertson, John S. Wai, Linghang Zhuang, Mark Embrey, Lekhhanh Tran, Jeffrey Y. Melamed, H. Marie Langford, James P. Guare, Thorsten E. Fisher, Samson M. Jolly, Michelle S. Kuo, Debra S. Perlow, Jennifer J. Bennett and Timothy W. Funk

For: AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS

For	Number Filed	Number Extra	Rate	Basic Fee \$740
Total Claims	36 - 20 =	16 X	\$18	= \$288
Independent Claims	4 - 3 =	1 X	\$84	= \$84
Multiple Dependent Claims*			\$280	=
* Add this fee if application contains any multiple dependent claims, regardless of number.			TOTAL FILING FEE →	\$1,112

Please charge my Deposit Account No. 13-2755 in the amount of \$ 1,112. The Assistant Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-2755. Duplicate copy of this sheet is enclosed.

Under the provisions of 37 C.F.R. §1.53, this application is being filed without the declaration of each inventor.

Respectfully,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732) 594-3462

Date: October 10, 2001

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT	<u>October 10, 2001</u>
EXPRESS MAIL NO.	<u>EL523938307US</u>
<p>I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.</p> <p>MAILED BY <u>G. Crowley</u> DATE <u>10/10/01</u></p>	

IN DUPLICATE

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Neville J. Anthony et al.	
Serial No.:	To Be Assigned	Case No.: 20757Y
Filed:	October 10, 2001	
For:	AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS	
Art Unit: To Be Assigned		
Examiner: To Be Assigned		

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE STATEMENT

Sir:

The following statements are made as required by 37 C.F.R. §1.821(f),
37 C.F.R. §1.825(a) and 37 C.F.R. §1.825(b).

I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

I hereby state that the copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the Sequence Listing.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Enclosures

Date: October 10, 2001

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 10, 2001
EXPRESS MAIL NO. EL523938307US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL, "POST OFFICE TO
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY G.B. Crowley
DATE 10/10/01